Literature DB >> 22269873

Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine.

Ryan L Vander Veen1, Alan T Loynachan, Mark A Mogler, Brandon J Russell, D L Hank Harris, Kurt I Kamrud.   

Abstract

A single-cycle, propagation-defective replicon particle (RP) vaccine expressing a swine influenza virus hemagglutinin (HA) gene was constructed and evaluated in several different animal studies. Studies done in both the intended host (pigs) and non-host (mice) species demonstrated that the RP vaccine is not shed or spread by vaccinated animals to comingled cohorts, nor does it revert to virulence following vaccination. In addition, vaccinated pigs develop both specific humoral and IFN-γ immune responses, and young pigs are protected against homologous influenza virus challenge. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22269873     DOI： 10.1016/j.vaccine.2012.01.030

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  17 in total

1.  An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.

Authors:  Laura J White; Carlos A Sariol; Melissa D Mattocks; Wahala Wahala M P B; Vorraphun Yingsiwaphat; Martha L Collier; Jill Whitley; Rochelle Mikkelsen; Idia V Rodriguez; Melween I Martinez; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

2.  Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs.

Authors:  Eugenio J Abente; Daniela S Rajao; Phillip C Gauger; Amy L Vincent
Journal:  Vaccine       Date:  2019-02-02       Impact factor: 3.641

3.  Short- and long-term protective efficacy against clade 2.3.4.4 H5N2 highly pathogenic avian influenza virus following prime-boost vaccination in turkeys.

Authors:  Jefferson J S Santos; Adebimpe O Obadan; Stivalis Cardenas Garcia; Silvia Carnaccini; Darrell R Kapczynski; Mary Pantin-Jackwood; David L Suarez; Daniel R Perez
Journal:  Vaccine       Date:  2017-09-06       Impact factor: 3.641

4.  All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines.

Authors:  Hongjun Chen; Matthew Angel; Weizhong Li; Courtney Finch; Ana Silvia Gonzalez; Troy Sutton; Jefferson Santos; Daniel R Perez
Journal:  J Virol       Date:  2014-06-18       Impact factor: 5.103

Review 5.  Swine influenza virus: Current status and challenge.

Authors:  Wenjun Ma
Journal:  Virus Res       Date:  2020-08-13       Impact factor: 3.303

6.  Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.

Authors:  Eugenio J Abente; Daniela S Rajao; Jefferson Santos; Bryan S Kaplan; Tracy L Nicholson; Susan L Brockmeier; Phillip C Gauger; Daniel R Perez; Amy L Vincent
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

7.  Bat influenza vectored NS1-truncated live vaccine protects pigs against heterologous virus challenge.

Authors:  Jinhwa Lee; Yonghai Li; Yuhao Li; A Giselle Cino-Ozuna; Michael Duff; Yuekun Lang; Jingjiao Ma; Sunyoung Sunwoo; Juergen A Richt; Wenjun Ma
Journal:  Vaccine       Date:  2021-03-11       Impact factor: 3.641

8.  Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle.

Authors:  John Dustin Loy; Jill Gander; Mark Mogler; Ryan Vander Veen; Julia Ridpath; Delbert Hank Harris; Kurt Kamrud
Journal:  Virol J       Date:  2013-01-28       Impact factor: 4.099

Review 9.  Optimal Use of Vaccines for Control of Influenza A Virus in Swine.

Authors:  Matthew R Sandbulte; Anna R Spickler; Pamela K Zaabel; James A Roth
Journal:  Vaccines (Basel)       Date:  2015-01-30

Review 10.  Replicon RNA Viral Vectors as Vaccines.

Authors:  Kenneth Lundstrom
Journal:  Vaccines (Basel)       Date:  2016-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.